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OBJECTIVES: To examine cost-effectiveness of oral triptan medications in Korea, 
and inform policymakers which triptan has the best/least value for money. METHODS: 
We conducted literature reviews to identify economic and clinical values of triptan 
therapy. The clinical value of triptans was estimated based on randomized controlled 
trials (RCT), systematic reviews, and meta-analyses. We refer to previously published 
economic evaluation studies of triptan medications for selection of outcome measures 
and design of the simulation model. We built a decision tree model to explore cost-
effectiveness of treating single attack in migraine patients. Outcome measures were 
2-hour pain free, sustained freedom from pain, and sustained freedom from pain 
without side effects, based on previous studies and clinical practice guidelines. Cost 
of treating migraine was estimated by using Korea’s national health insurance claims 
database. Societal perspective was taken. One-way sensitivity analyses, as well as 
probabilistic sensitivity analyses, were conducted. RESULTS: Naratriptan, Sumatrip-
tan, and Zolmitriptans are listed in the Korean National Health Insurance Drug List 
as of 2007. The efﬁ cacy of Naratriptan is inferior to Sumatriptan and Zolmitriptan 
in terms of 2-hour pain free, sustained freedom from pain, and sustained freedom 
from pain without adverse events. Cost-effectiveness analysis suggests that Naratrip-
tan and Zolmitriptan are dominated by Sumatriptan in terms of the three observed 
outcome measures. Sensitivity analyses suggest that our results were robust under 
different assumptions. CONCLUSIONS: Naratriptan and Zolmitriptan are dominated 
by Sumatriptan in terms of 2-hour pain free, sustained freedom from pain, sustained 
freedom from pain without side effects. Our results should be interpreted with caution, 
since Naratriptan and Zolimitriptan may have other values which could not be mea-
sured in our study. 
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes 
Studies
PSY8
ACCESS TO CARE AND HEALTH OUTCOMES AMONG THE SEVERE 
HEMOPHILIA A POPULATION IN CHINA TODAY
Zhang M1, Epstein JD2, Li-McLeod J2, Xiong Y2
1Baxter Asia Paciﬁ c, Shanghai, China; 2Baxter Bioscience, Westlake Village, CA, USA
OBJECTIVES: Hemophilia care in China is at a nascent stage and efforts to improve 
care require a better understanding of current treatment standards, clinical outcomes, 
and patient health-related quality of life (HRQOL) in China relative to other countries. 
METHODS: Severe hemophilia A patients and their caregivers in China (Beijing and 
Shanghai), Russia, Argentina, and the United States completed a cross-sectional survey 
of treatment and health outcomes in 2009. HRQOL was measured using the PEDS-QL 
for children, the SF-12 for adults and the EQ-5D for all patients. [Due to recruitment 
methods, the Chinese patient cohort may not be representative of the average Chinese 
hemophilia patient.]. RESULTS: A total of 160, 167, 57, and 117 patients in China, 
Russia, Argentina and the United States completed the survey, respectively. On 
average, while Russian, Argentine, and American patients reported being diagnosed 
within the ﬁ rst year after birth, Chinese patients waited 6 years. Only 18% of the 
Chinese patients are able to receive FVIII to treat bleeds all of the time, while it is 
53%, 86% and 91% for Argentina, Russia and the United States (chi-square P < 
0.0001). Chinese hemophilia children scored an average of 38.4 on the physical 
functioning domain of the PEDS-QL; signiﬁ cantly lower than Argentina (61.5), Russia 
(60.6) and the United States S (82.9) (all P < 0.0001). Chinese hemophilia adults 
reported an average of 33.9 on the SF-12 physical component summary which was 
signiﬁ cantly lower than patients in Argentina (39.3), Russia (37.4) and the United 
States (39.8) (all P < 0.01). The average EQ-5D health utility score was signiﬁ cantly 
lower in China (0.49) compared with 0.75, 0.73 and 0.80 in Argentina, Russia and 
the United States, respectively (all P < 0.0001). CONCLUSIONS: There is substantial 
room to improve the HRQOL for Chinese hemophilia patients. Improving access to 
hemophilia care and Factor VIII treatment may improve health outcomes and thus 
HRQOL. 
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OBJECTIVES: Impact of chronic immune thrombocytopenic purpura (ITP) and its 
treatments on quality of life (QoL) was explored. METHODS: As the modiﬁ ed genera-
tive round, a questionnaire composed of 29 items was developed through literature 
review and focus group discussion. Then 2-round web based delphi survey was con-
ducted with 11 panelists who were key hematologists and treating most of the ITP 
patients in Korea. The panelists were asked to make a choice on main discomforts 
that generally affect ITP patients’ QoL and rate the health of non-refractory and 
refractory patients using EQ5D and VAS. Furthermore, they were requested to indi-
cate their level of agreement on possible aspects of QoL, based on 5-point likert scale. 
RESULTS: The nearly unanimous consensus was made that major factors affecting 
QoL were consistent bruising, limitation of physical & social activities and psychologi-
cal distress at bleeding risk. The utility derived from rated QoL for non-refractory ITP 
was 0.717 for EQ5D and 56.4 for VAS and that for refractory ITP was 0.422 for 
EQ5D and 47.7 for VAS. The considerable impairment of QoL was ﬁ gured out for 
overall chronic ITP patients compared with general population and the decrement of 
QoL for refractory patients was found far more serious than non-refractory patients 
(Mean difference of 0.295 for EQ5D). It was also concluded that economic burden 
from non-reimbursement drug uses was signiﬁ cant determinants of diminution of 
QoL, in addition to increased risk of bleeding and cumulated side effects from tryouts. 
CONCLUSIONS: ITP and its treatments negatively impact on QoL and most seriously 
in refractory patients. The treatment that effectively prevents and manages refractory 
ITP would beneﬁ t health-related QoL in chronic ITP patients. 
SYSTEMIC DISORDERS/CONDITIONS – Health Care Use & Policy Studies
PSY10
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OBJECTIVES: This study is aimed to descriptively analyze the treatment strategies of 
neuropathic pain (NeP) in a pain specialist setting. METHODS: A retrospective 
medical chart review for 266 new NeP patients attending the pain clinic in Siriraj 
hospital, a tertiary care hospital, over a period of 18 months (January 2008–June 
2009) was performed. Collected data included patient characteristics, comorbidities, 
types of NeP, and the use of pharmacological and non-pharmacological treatments. 
RESULTS: Patients were predominantly female (57.1%) with a mean age of 56 years. 
Mixed NeP was found to be the most common NeP (60.9%) whereas pure NeP 
accounted for 39.1%. Over two-thirds of the patients (79.3%) were newly diagnosed 
at the pain clinic, and a small proportion were diagnosed and referred from other 
hospital departments (17.3%) and other hospitals (3.4%). Common comorbidities 
were musculoskeletal disorder (32.7%), malignancy (29.3%) while hypertension and 
diabetes were less frequently found. Opioids (O) (29.5%) and anti-epileptic drugs (E) 
(28.8%) represented the majority of drugs used whereas the use of antidepressants 
(D) and NSAIDs accounted for 18.4% and 10.6% respectively. Intervention for pain 
relief was prescribed at 1.7%. In mixed NeP, O were the most common drug (32.9%) 
while E were most often prescribed in pure NeP (33.0%). We found the three-drug 
combination (O + E + D) was the most common (37.8%) treatment strategy. The 
four-drug combination (O + E + D + NSAIDs) was the second most common strategy 
(33.0%). The two-drug combination (O + E) and single drug (E) accounted for 14.8% 
and 3.4% respectively. Considering the type of NeP, the most prevalent treatment 
strategy in pure NeP and mixed NeP was the three-drug combination (44%) and the 
four-drug combination (36.2%) respectively. CONCLUSIONS: NeP treatment strate-
gies using more than two drugs from different therapeutic areas were commonly used 
in the pain specialist setting. This is due to pain symptoms in NeP being complex and 
frequently associated with other comorbidities. 
URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: To compare the risk of death between peritoneal dialysis (PD) and 
hemodialysis (HD) patients. METHODS: Through the national health-care insurance 
(NHI) database, we identiﬁ ed a national cohort of 66,080 patients initiating dialysis 
therapy between January 1, 1998 and December 31, 2006 and followed a maximum 
of 9 years. To compare the survival functions between PD and HD patients, the 
Kaplan-Meier life table was applied. Both proportional and non-proportional Cox 
regression models were conducted to evaluate the relative hazard of death by dialysis 
modality using the intention-to-treat (ITT) approach. Three propensity score strategies 
were applied to achieve covariate balance, matching, stratiﬁ cation, and regression 
adjustment. Subsets analyses were deﬁ ned by age and diabetes mellitus (DM), and 
sensitivity analyses were conducted by the logit propensity score. RESULTS: The 
results showed that the hazard ratios (HRs) of PD and HD patients varied by age and 
with/without DM. Among patients under age 49 with or without DM, PD was associ-
ated with a lower risk of death. Among patients aged 50–59, the HR of PD relative 
to HD was higher for those with DM but was lower for those without DM. For 
patients aged over 60 with or without DM, the HRs were higher on PD than on HD. 
We also found that the HRs for PD and HD were not proportional over time. The 
risk of death for PD patients was generally lower during the ﬁ rst year or ﬁ rst 2 years 
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after the onset of dialysis. Thereafter, the risk of death increased on PD patients. 
Results were consistent in different propensity score models and in sensitivity analyses. 
CONCLUSIONS: In conclusion, there was an initial survival advantage of PD com-
pared with HD among younger or non-DM patients. As the increase in age, with the 
presence of DM, and vintage, this relative survival advantage vanished, and even 
reversed. 
URINARY/KIDNEY DISORDERS – Cost Studies
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OBJECTIVES: To compare health-care resource consumption associated with the 
long-term treatment of peritoneal dialysis (PD) and hemodialysis (HD) patients. 
METHODS: Using Taiwan’s National Health Insurance Database, we identiﬁ ed all 
ESRD patients beginning dialysis between January 1, 1998 and December 31, 2004 
and tracked their health-care resource consumption (deﬁ ned as reimbursement medical 
points) for 3 years. Only patients with 90 days or more of treatment follow-up were 
included. For patients whose treatments were followed less than 36 months, resource 
consumption was prorated based on the period observed. Annual resources consumed 
by patients using different modalities were calculated. Both intention-to-treat (ITT) 
and as-treated (AT) approaches were employed. In AT analyses, patients were further 
divided into eight subgroups to understand the effect of modality transfer. We further 
conducted regression analyses to adjust for patient characteristics. RESULTS: A total 
of 48,565 patients met the study criteria, with 93.9% initiating HD and 6.1% initiat-
ing PD. In ITT analysis, the annual total health-care resource consumption for HD 
patients was higher than that for PD patients by 119,085 points. Compared to HD 
patients without switch, annual total health-care resource consumption for PD 
patients without switch was lower by 143,715 points in AT analysis. Those patients 
switching from HD to PD in any study year, or from PD to HD in the second or third 
treatment year, also consumed fewer resources. Higher resource consumption (12,556 
points) occurred only in the 6.6% of PD patients with ﬁ rst-year switch to HD. 
CONCLUSIONS: Three-year aggregated treatment cost is highest in incident PD 
patients who switch to HD within the ﬁ rst year of treatment and lowest in PD patients 
without switch. Nonetheless, compared to patients starting HD without switch, PD 
demonstrated overall resource savings capacity in the incident dialysis population. 
Over 93%of patients beginning dialysis with PD demonstrated resource savings com-
pared to less than 2% of those starting HD. 
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes Studies
PUK5
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OBJECTIVES: To compare the utility scores of hemodialysis patients obtained from 
the EQ-5D (Euroqol), VAS (Visual Analog Scale), and SF-6D (Short Form-6 Dimen-
sions which developed from SF-36) and to analyze the relationship between the utility 
scores and the HRQoL scores using KDQOL-SF (Kidney Disease Quality of Life Short 
Form) disease speciﬁ c questionnaire. METHODS: This study was a cross-sectional 
study. Face-to-face interview included KDQOL-SF (consist of SF-36 and kidney 
disease questionnaires) and EQ-5D was conducted during November–December 2009 
with 155 patients receiving hemodialysis at Siriraj hospital. Not only the correlation 
coefﬁ cient was compared across the different measurement tools but the Bland and 
Altman plot was also used to graphically illustrate the agreement of instruments. 
RESULTS: Patient samples had the mean age of 57.28 ± 14.49 years and been hemo-
dialised on the average for 7.70 ± 5.07 years. The mean SF-6D score was 0.749 ± 
0.139 showing signiﬁ cantly higher than EQ-5D (0.686 ± 0.322), and VAS (0.654 ± 
0.310) scores. The Pearson’s correlation coefﬁ cients between utility scores with kidney 
disease speciﬁ c questionnaires illustrated that all three utility scores correlated well 
with the dimension of Symptoms and Problems, but were low associated with Burden 
of Kidney Disease and Effects of Kidney Disease on Daily Life dimensions. Of these 
three disease speciﬁ c dimensions, the SF-6D showed higher relationship on two dimen-
sions. The Bland-Altman plots also suggested a pattern of agreement in favor of SF-6D 
with kidney speciﬁ c dimensions. CONCLUSIONS: Utility scores from SF-6D, EQ-5D, 
and VAS illustrated consistent results with highest score on SF-6D. The SF-6D pre-
sented better agreement with kidney speciﬁ c scales than EQ-5D and VAS. These 
ﬁ ndings implied that SF-6D could, to a certain extent, reﬂ ect HRQoL status of hemo-
dialysis patients and might be use as the only QOL instrument for patient care to 
avoid patients’ burden on answering multiple questionnaires. 
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OBJECTIVES: Nocturia has been reported to negatively affect health-related quality 
of life (QOL), for example, quality of sleep, daytime activities and psychological well-
ness The Nocturia Quality of Life Questionnaire (N-QOL) was developed in 2004 in 
the UK to assess the QOL of patients with nocturia. It has been translated into 17 
languages. The purpose of this study was to assess the psychometric properties of the 
Japanese version of the N-QOL. METHODS: Psychometric properties were assessed 
in 121 Japanese men and women experiencing nocturia at least once a night. The 
questionnaire used in this study included the Japanese version of the N-QOL as well 
as several other instruments: the Pittsburgh Sleep Quality Index (PSQI), the Epworth 
Sleepiness Scale (ESS), the International Prostate Symptom Score (IPSS), the Overactive 
Bladder questionnaire Short Form (OAB-q SF) and the Medical Outcomes Study Short 
Form-36 ver. 2 (SF-36v2). RESULTS: For concurrent validity, the N-QOL overall 
score correlated moderately with the overall scores of PSQI, IPSS, OAB-q SF, and 
Physical Component Summary measure of SF-36v2, respectively, although the correla-
tion was weak with ESS. For discriminant validity, statistically signiﬁ cant differences 
were found among the scores of those experiencing one, two, or three or more episodes 
of nocturia. For construct validity, the structure could be considered almost the same 
as the original; one factor was found to belong to a subscale different from the original 
analysis. For reliability, the Cronbach’s alpha coefﬁ cients ranged from 0.87 to 0.93, 
providing evidence of internal consistency. CONCLUSIONS: The Japanese version of 
the N-QOL demonstrated validity and reliability, and appears to be suitable for clini-
cal use. 
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OBJECTIVES: This objective of this research was to describe the quality of life of 
Malaysian renal failure patients who are on dialysis awaiting a potential transplant 
at 6 Malaysian Government hospitals. METHODS: This study utilizes primary data 
collected in 2009 for an ongoing study on the cost-effectiveness of Renal Transplants. 
The EQ-5D questionnaire was self-administered by Malaysian renal failure patients 
on dialysis who are currently on the transplant waiting list. Respondents answered 
validated Malaysian English, Malay or Malaysian Chinese versions of the EQ-5D 
questionnaire comprising 1) rating of the ﬁ ve EQ-5D dimensions of health and 2) 
visual analogue scale (VAS) of their own health, respondent demographics and percep-
tions. The results from this study were compared against the QOL of Malaysian dialy-
sis patients from a 2004–2005 study by Faridah. RESULTS: A total of 208 respondents 
answered the questionnaire. Of these 195 were useful for analysis. Mean age was 
41  years in the sample of which 54% were male and 75% had a secondary or tertiary 
level education. Most patients opted to answer the Malay language questionnaire 
(83%), compared to the English (6%) and Chinese (11%) language versions. Mean 
quality of life for the entire sample was a VAS score of 77.7 (SD 14). Very few 
respondents reported extreme problems in any health dimension. The highest rate of 
extreme problems was 2% for usual activity. Quality of life was found to be related 
to age and how the respondent felt on the day. The relationships were statistically 
signiﬁ cant. CONCLUSIONS: The EQ-5D appears to be able to measure the QOL of 
Malaysian dialysis patients. QOL of dialysis patients from this survey are similar the 
results from a previous study conducted in 2004–2005. 
